Tag: 2018
ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 2 Phase 3 Clinical Trial of Linzagolix for the Treatment of Heavy Menstrual Bleeding Associated with Uterine Fibroids
Geneva, Switzerland and Boston, MA – December 21, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical- stage biopharmaceutical company focused on the development and commercialization of novel…
ObsEva R&D Day Showcases Multiple Women’s Health Programs and Outlines Plans for Transition to Commercial Operations
Clinical Trial Data and Regulatory Progress on Lead Programs Targeting IVF, Endometriosis, and Uterine Fibroids to Transform Company in 2019 GENEVA, Switzerland and BOSTON,…
R&D Investor Day
Click here for webcast Date & Time: Friday, December 7, 2018 8:30 a.m. ET Location: New York City
ObsEva SA to Participate in BMO Healthcare Conference December 12, 2018
Geneva, Switzerland and Boston, MA – December 6, 2018 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…
ObsEva SA to Host R&D Investor Day December 7, 2018
Geneva, Switzerland and Boston, MA – November 29, 2018 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on developing and commercializing novel…
ObsEva SA Announces Initiation of Phase 3 IMPLANT 4 Trial of Nolasiban in Europe, Canada and Russia for Improving IVF Outcomes
Geneva, Switzerland and Boston, MA – November 28, 2018 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…
Credit Suisse Healthcare Conference
Click here for webcast Date & Time: 15 Nov 2018 10:00 a.m. ET Location: Scottsdale, AZ
Jefferies London Healthcare Conference
Click here for webcast Date & Time: 14 Nov 2018 10:00 a.m. GMT Location: London